Researchers have developed a new compound, called S-181, that can improve nerve cell function and decrease the build-up of disease-related harmful molecules by boosting the activity levels of the enzyme beta-glucocerebrosidase. That enzyme’s function is known to be compromised in Parkinson’s disease. The findings, “A modulator of…
The levels of calprotectin — a protein whose levels increase in response to tissue inflammation — in the stool may be used as a marker of bowel inflammation in patients with Parkinson’s disease, according to a recent study. The results, “Fecal Calprotectin as a Marker of the Gut…
To provide new patients with the information, tools and resources they need to best manage their health, the Parkinson’s Foundation has launched a campaign to close the gap between learning of an illness and knowing how and where to find help. Called “Newly Diagnosed: Building a Better Life with Parkinson’s…
People with bipolar disorder have a significantly increased risk — more than three times that of the general population — of later developing Parkinson’s disease, a study has found. Although use of medications for bipolar disorder could overestimate this risk, the researchers believe that a Parkinson’s diagnosis should…
Kyowa Kirin’s Nourianz (istradefylline) tablets are now available in the United States as an add-on treatment for off periods in Parkinson’s disease patients on a carbidopa/levodopa regimen. Off periods — when the effects of a medication wear off before a new dose can be taken — are characterized…
Taking several different medications at the same time to treat concurrent health conditions — known as polypharmacy — may be associated with cognitive decline in people newly diagnosed with Parkinson’s disease, according to a recent study. Reducing the number of medications prescribed would be one option to…
Military veterans with post-traumatic stress disorder (PTSD) or who experienced a traumatic brain injury have more than double the risk of a rare sleep disorder — called rapid eye movement (REM) sleep behavior disorder — previously reported as a risk factor for Parkinson’s disease, a study finds. Researchers at…
A detailed analysis of alpha-synuclein — a key protein involved in Parkinson’s — revealed how variants of this protein change over time, allowing researchers to identify the initial stages of protein aggregation involved in early onset disease. These findings provide new insights into how genetic mutations — especially…
A planned Phase 2 clinical trial will assess the safety and effectiveness of pharmaceutical-grade cannabidiol (CBD) in treating Parkinson’s-related psychosis. The trial was announced by Parkinson’s UK, which is investing £1.2 million (roughly $1.5 million) to support the study, due to begin enrolling patients in 2020. Psychosis…
Using its brain mapping platform, Inscopix will team up with researchers at the Broad Institute of MIT and Harvard to investigate how changes in brain activity alter the functioning of nerve cells. The goal is to identify new therapeutic targets for Parkinson’s disease. The collaboration will be led…
Get regular updates to your inbox.
